Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Age groups; Gastrointestinal neoplasms; TrifluridineGrupos de edad; Neoplasias gastrointestinales; TrifluridinaGrups d'edat; Neoplàsies gastrointestinals; TrifluridinaBackground Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS examined efficacy/safety outcomes by age. Methods In TAGS, patients with mGC/GEJC and ≥ 2 prior therapies were randomized (2:1) to receive FTD/TPI 35 mg/m2 or placebo, plus best supportive care. A preplanned subgroup analysis was performed to evaluate efficacy and safety outcomes in patients aged < 65, ≥ 65, and ≥ 75 years. Results Among 507 randomized patients (n = 337 FTD/TPI; n = 170 placebo), 55%, 45%, and 14% were aged < 65, ≥ 65, and ≥ 75 years, respectively. Overall survival hazard ratios for FTD/TPI vs placebo were 0.67 (95% CI 0.51–0.89), 0.73 (95% CI 0.52–1.02), and 0.67 (95% CI 0.33–1.37) in patients aged < 65, ≥ 65, and ≥ 75 years, respectively. Regardless of age, patients receiving FTD/TPI experienced improved progression-free survival and stayed longer on treatment than those receiving placebo. Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]. Conclusions The results of this subgroup analysis show the efficacy and tolerability of FTD/TPI treatment regardless of age in patients with mGC/GEJC who had received 2 or more prior treatments.This study was sponsored by Taiho Oncology, Inc., and Taiho Pharmaceuticals Co., Ltd. Professional medical writing and editorial assistance were provided by Vasupradha Vethantham, PhD, and Jennifer L. Robertson, PhD, at Ashfield MedComms, an Ashfield Health company, funded by Taiho Oncology, Inc

Solitary Peutz-Jeghers Type Colorectal Polyp with Hamartonia-adenoma-carcinoma Sequence in a Non-Peutz-Jeghers Syndrome Patient

Peutz-Jeghers (P-J) syndrome is an inherited disorder characterized by multiple hamartomatous gastrointestinal polyps, mucocutaneous pigmentation, and an increased risk of both digestive tract and non-digestive tract cancers. P-J type polyps are characteristic of P-J syndrome but rarely present as solitary polyps. Though cancerous lesions frequently develop from polyposis in P-J syndrome, reports of malignancy in solitary colorectal P-J type polyps are rare; our literature search identified only two examples. This report describes a non-Peutz-Jeghers syndrome patient with a solitary P-J type polyp showing the hamartoma-adenoma-carcinoma sequence

GRENE-TEA Model Intercomparison Project (GTMIP): Stages 1 & 2

第6回極域科学シンポジウム分野横断セッション：[IA] 急変する北極気候システム及びその全球的な影響の総合的解明―GRENE北極気候変動研究事業研究成果報告2015―11月19日（木）　国立極地研究所 2階 大会議

Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose

We assessed SARS-CoV-2 anti-spike immunoglobulin G (anti-S-IgG) levels among healthcare workers (HCWs) after BNT162b2 vaccination. The anti-S-IgG titers of study participants were measured every three months, a week before, and three weeks after each vaccination. This study compared the short-term immune response to the second vaccination in four HCWs who received the first two doses six months apart (due to acute allergic-like adverse events after the first dose), with that of six HCWs who received the first two doses three weeks apart, according to the standard schedule. The four HCWs who experienced acute allergic-like adverse events after the first vaccination took antihistamines before the second vaccination. None of them experienced an allergic-like reaction after the second vaccination, and the short-term immune response to the second vaccination was similar in both groups

Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose

We assessed SARS-CoV-2 anti-spike immunoglobulin G (anti-S-IgG) levels among healthcare workers (HCWs) after BNT162b2 vaccination. The anti-S-IgG titers of study participants were measured every three months, a week before, and three weeks after each vaccination. This study compared the short-term immune response to the second vaccination in four HCWs who received the first two doses six months apart (due to acute allergic-like adverse events after the first dose), with that of six HCWs who received the first two doses three weeks apart, according to the standard schedule. The four HCWs who experienced acute allergic-like adverse events after the first vaccination took antihistamines before the second vaccination. None of them experienced an allergic-like reaction after the second vaccination, and the short-term immune response to the second vaccination was similar in both groups